Amylyx reports positive topline data from LUCIDITY trial on avexitide

Amylyx announced positive results from a Phase 3 trial of avexitide for post-bariatric hypoglycemia, showing a statistically significant reduction in severe hypoglycemic events. The company plans to file a New Drug Application with the FDA by year-end.